Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

  • PHASE II STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Aim Phase II multi-disease randomized discontinuation trial to assess the safety and efficacy of sorafenib including patients with advanced soft tissue sarcoma (STS). Methods Sorafenib (400 mg twice daily) was initially administered for 12 weeks. Patients with: ≥25% tumour shrinkage continued sorafenib; ≥25% tumour growth discontinued; other patients were randomized and received sorafenib or placebo. Results Twenty-six patients (median age 55 years) were enrolled. Common drug-related adverse events, including fatigue, hand–foot skin reaction, rash or gastrointestinal disturbances, were manageable, reversible and generally low grade. Fatigue, skin toxicity, nausea, diarrhoea and hypertension occurred at grade ≥3 in 19% of patients. After 12 weeks eight (31%) patients had not progressed. Three patients who experienced tumour shrinkage and continued on sorafenib, and five (19%) were randomized either to continue sorafenib or to receive placebo. Of the three patients randomized to sorafenib, one achieved a partial response and two had SD. Overall one patient achieved a partial response and three further patients achieved minor responses. Conclusions There was evidence of disease activity in STS as defined by tumor regressions including one objective partial response. Further investigation in STS is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. George S (2007) Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Curr Oncol Rep 9(4):323–327

    Article  PubMed  CAS  Google Scholar 

  2. Siehl J, Thiel E (2007) C-kit, GIST, and imatinib. Recent Results Cancer Res 176:145–151

    Article  PubMed  CAS  Google Scholar 

  3. Van GM, van Oosterom AT, Oosterhuis JW et al (1999) Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2, 185 patients treated with anthracycline-containing first-line regimens–a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17(1):150–157

    Google Scholar 

  4. Nielsen OS, Judson I (2000) van HQ, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36(1):61–67

    Article  PubMed  CAS  Google Scholar 

  5. Nielsen OS, Dombernowsky P, Mouridsen H et al (1998) High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 78(12):1634–1639

    Article  PubMed  CAS  Google Scholar 

  6. Judson I, Radford JA, Harris M et al (2001) Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37(7):870–877

    Article  PubMed  CAS  Google Scholar 

  7. Benjamin RS, Rouesse J, Bourgeois H, van Hoesel QG (1998) Should patients with advanced sarcomas be treated with chemotherapy? Eur J Cancer 34(7):958–965

    Article  PubMed  CAS  Google Scholar 

  8. Penel N, Nisse C, Feddal S, Lartigau E (2001) Epidemiology of soft tissue sarcomas in adults. Presse Med 30(28):1405–1413

    PubMed  CAS  Google Scholar 

  9. Penel N, Nisse C, Feddal S, Lartigau E (2001) Epidemiology of soft tissue sarcomas in adults. Presse Med 30(28):1405–1413

    PubMed  CAS  Google Scholar 

  10. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127–1134

    Article  PubMed  CAS  Google Scholar 

  11. Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531–2541

    Article  PubMed  CAS  Google Scholar 

  12. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338

    Article  PubMed  CAS  Google Scholar 

  13. Kasper B, Gil T, D’Hondt V, Gebhart M, Awada A (2007) Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 62(1):9–15

    Article  PubMed  Google Scholar 

  14. Wilhelm S, Chien DS (2002) BAY 43–9006: preclinical data. Curr Pharm Des 8(25):2255–2257

    Article  PubMed  CAS  Google Scholar 

  15. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099–7109

    Article  PubMed  CAS  Google Scholar 

  16. Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965–972

    Article  PubMed  CAS  Google Scholar 

  17. Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965–972

    Article  PubMed  CAS  Google Scholar 

  18. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134

    Article  PubMed  CAS  Google Scholar 

  19. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505–2512

    Article  PubMed  CAS  Google Scholar 

  20. Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965–972

    Article  PubMed  CAS  Google Scholar 

  21. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390

    Article  PubMed  CAS  Google Scholar 

  22. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099–7109

    Article  PubMed  CAS  Google Scholar 

  23. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505–2512

    Article  PubMed  CAS  Google Scholar 

  24. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49(17):4682–4689

    PubMed  CAS  Google Scholar 

  25. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954

    Article  PubMed  CAS  Google Scholar 

  26. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505–2512

    Article  PubMed  CAS  Google Scholar 

  27. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505–2512

    Article  PubMed  CAS  Google Scholar 

  28. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214

    Article  PubMed  CAS  Google Scholar 

  29. Maki RG, D’Adamo DR, Keohan ML et al (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol May 18

  30. Ryan CW, von Mehren M, Rankin CJ et al (2008) Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. J Clin Oncol 26:10532

    Google Scholar 

  31. Wiebe L, Kasra KE, Maki RG et al (2008) Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 26(suppl):10502

    Google Scholar 

  32. Reichardt P, Montemurro M, Gelderbloom H et al (2009) Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: a retrospective analysis. J Clin Oncol 27(15s):10564

    Google Scholar 

  33. Tap WD, Federman N, Eilber FC (2007) Targeted therapies for soft-tissue sarcomas. Expert Rev Anticancer Ther 7(5):725–733

    Article  PubMed  CAS  Google Scholar 

  34. Kasper B, Gil T, D’Hondt V, Gebhart M, Awada A (2007) Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 62(1):9–15

    Article  PubMed  Google Scholar 

  35. Sleifer S, Papai Z, Le CA et al (2007) Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043. J Clin Oncol 25(18S):10031

    Google Scholar 

  36. Heymach JV, Desai J, Manola J et al (2004) Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10(17):5732–5740

    Article  PubMed  CAS  Google Scholar 

  37. Guida T, Anaganti S, Provitera L et al (2007) Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor beta Gatekeeper Mutants. Clin Cancer Res 13(11):3363–3369

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Assistance in drafting this manuscript was provided by Chameleon and paid for by Bayer Pharmaceuticals Ltd. Bayer held the database, provided statistical support and provided information on toxicity and response. Bayer was not involved in the decision to publish the data on sarcoma or in the interpretation of the data. Dr A Patnaik assisted with patient recruitment and treatment.

Author information

Authors and Affiliations

  1. The Royal Marsden Hospital, Downs Rd, Sutton, Surrey, SM2 5PT, UK

    Simon Pacey, Stanley B. Kaye & I. R. Judson

  2. University of Chicago Hospitals, 5841 S. Maryland Avenue, MC2115, Chicago, IL, 60637, USA

    Mark J. Ratain

  3. Abramson Cancer Center of the University of Pennsylvania, 1222 Penn Tower, 34th & Spruce Streets, Philadelphia, PA, 19104, USA

    Keith T. Flaherty

  4. Bayer Pharmaceuticals Corporation, 6 West Belt, Wayne, NJ, 07470, USA

    Lisa Cupit & Chenghua Xia

  5. ImClone Systems, 33 ImClone Drive, Branchburg, NJ, 08876, USA

    Eric K. Rowinsky

  6. Developmental Therapeutics, Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA, 19014, USA

    Peter J. O’Dwyer

Authors
  1. Simon Pacey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark J. Ratain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keith T. Flaherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stanley B. Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lisa Cupit
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eric K. Rowinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chenghua Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Peter J. O’Dwyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I. R. Judson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. R. Judson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pacey, S., Ratain, M.J., Flaherty, K.T. et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs 29, 481–488 (2011). https://doi.org/10.1007/s10637-009-9367-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-009-9367-9

Keywords

Search

Navigation